Skip to main content
. Author manuscript; available in PMC: 2008 Sep 1.
Published in final edited form as: Oncogene. 2006 Aug 28;26(8):1188–1200. doi: 10.1038/sj.onc.1209901

Figure 4.

Figure 4

Bcr-Abl and mTORC1 induce the formation of eIF4F in primary chronic phase CML cells. Left hand panel: primary CML cells obtained at presentation from a patient in chronic phase were grown in GF-supplemented serum-free media, and treated with or without imatinib (2μM), rapamycin (10 ng/ml), or both for 24 hrs. Cap-bound eIF4E and 4E-BP1 were assessed by immunoblot. Right hand panel: densitometric analysis of cap-bound 4E-BP1 was performed, and data plotted as an average from two independent experiments.